Partnership between ABPI and West Midlands health organisations aims to tackle local health challenges
Birmingham Health Partners (BHP) and the ABPI are collaborating to create the Birmingham Health Partners Industry Steering Group (BHPISG), with the aim of accelerating the development of data-driven health innovations and becoming a world leader in precision medicine.
This initiative aims to build upon success of ABPI’s first city partnership with Greater Manchester, helping to accelerate healthcare innovation and make use of real-time clinical data.
Mayor of the West Midlands, Andy Street, commented that:
“With a diverse population of nearly six million citizens, the West Midlands is the ideal place to develop and test new innovations in healthcare, such as precision medicines tailored to individual patient needs.
“This exciting agreement will bring world-class researchers, healthcare practitioners and industry together to tackle the big health challenges facing our region and help deliver on our West Midlands Local Industrial Strategy.
“It also demonstrates the strength of the West Midlands life sciences cluster, which is rapidly emerging as a flagship location for developing and testing innovations in healthcare.”
The BHPISG will have a particular focus upon issues prevalent in the area but aims to be pertinent and scalable on a national or international level, including improving:
- cancer outcomes – Birmingham has average cancer incidence rates but higher mortality rates, thus the BHPSIG will build upon the work of the West Midlands Genomic Medical Centre to accelerate data collection for, and uptake of, new cancer treatments
- maternal and paediatric health – Birmingham has one of the youngest populations in Europe and the only single-specialist Foundation Trust for both women and children in England. There will be a focus upon childhood obesity, paediatric conditions and miscarriage, particularly those caused by genetic conditions
- multimorbidity in the elderly – around 15-20% of Birmingham’s population are retired and many suffer multimorbidities; the BHPSIG will use data to develop new medicines to treat common conditions
- clinical trials – the BHPISG aim to adopt innovative approaches to clinical trial design and assessment, testing new therapies upon similar diseases in order to quickly ascertain efficacy
Chief Executive of the ABPI and co-chair of the new Steering Group, Mike Thompson, commented that:
“This partnership will accelerate cutting-edge research in Birmingham and help the NHS tackle some of the West Midlands’ most pressing health challenges. We’re playing to our strengths: linking state-of-the-art science from pharmaceutical companies with Birmingham’s internationally recognised data and genomics infrastructure.
“Together, we can cement Birmingham as a world-class research centre and deliver better care for patients throughout the West Midlands.”
See the ABPI’s announcement on the new initiative here.